Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition
May Commercialize Therapy Alone
The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.
